Genmab A/S (LON:0MGB)

Market Cap	11.15B
Revenue (ttm)	2.39B
Net Income (ttm)	869.80M
Shares Out	n/a
EPS (ttm)	13.46
PE Ratio	12.82
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,228
Average Volume	24,885
Open	1,554.00
Previous Close	1,540.00
Day's Range	1,535.25 - 1,592.00
52-Week Range	154.65 - 246.44
Beta	0.86
RSI	67.49
Earnings Date	Feb 14, 2025

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 2,682
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MGB

Financial Performance

In 2024, Genmab's revenue was 21.53 billion, an increase of 30.67% compared to the previous year's 16.47 billion. Earnings were 7.84 billion, an increase of 80.24%.

Financial numbers in DKK